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The worldwide increase in the prevalence of Diabetes mellitus (DM) has highlighted the
need for increased research efforts into treatment options for both the disease itself and its
associated complications. In recent years, mesenchymal stromal cells (MSCs) have been
highlighted as a new emerging regenerative therapy due to their multipotency but also
due to their paracrine secretion of angiogenic factors, cytokines, and immunomodulatory
substances.This review focuses on the potential use of MSCs as a regenerative medicine
in microvascular and secondary complications of DM and will discuss the challenges and
future prospects of MSCs as a regenerative therapy in this field. MSCs are believed to
have an important role in tissue repair. Evidence in recent years has demonstrated that
MSCs have potent immunomodulatory functions resulting in active suppression of various
components of the host immune response. MSCs may also have glucose lowering proper-
ties providing another attractive and unique feature of this therapeutic approach. Through
a combination of the above characteristics, MSCs have been shown to exert beneficial
effects in pre-clinical models of diabetic complications prompting initial clinical studies in
diabetic wound healing and nephropathy. Challenges that remain in the clinical translation of
MSC therapy include issues of MSC heterogeneity, optimal mode of cell delivery, homing of
these cells to tissues of interest with high efficiency, clinically meaningful engraftment, and
challenges with cell manufacture. An issue of added importance is whether an autologous
or allogeneic approach will be used. In summary, MSC administration has significant poten-
tial in the treatment of diabetic microvascular and secondary complications but challenges
remain in terms of engraftment, persistence, tissue targeting, and cell manufacture
Keywords: mesenchymal stromal cell, MSC, diabetes, microvascular complication, retinopathy, nephropathy,
neuropathy
INTRODUCTION
Diabetes mellitus (DM) is a heterogeneous group of metabolic dis-
orders characterized by hyperglycemia with impaired metabolism
of carbohydrate, fat, and proteins as a result of defects in insulin
secretion, insulin action, or both (1). Diabetes is one of the world’s
oldest diseases and it has been centuries since this syndrome was
first recognized (2, 3). Considered previously as a disease of the
affluent, diabetes is now considered an epidemic. The world preva-
lence of DM in 2010 was estimated at 6.4% or 285 million adults
and it is expected this number will rise to 439 million adults in
2030. Most of this increase will occur in developing countries (4).
Type 1 DM (T1DM) is caused by β-cell destruction. The patho-
genesis of T1DM is the autoimmune destruction of the pancreatic
β-cells that leads to loss of insulin secretion and absolute insulin
deficiency. Type 2 DM (T2DM) is caused by a combination of
genetic and non-genetic factors that result in insulin resistance
and insulin deficiency. Non-genetic factors include increasing age,
high caloric intake, obesity, central adiposity, sedentary lifestyle,
and low birth weight. This group comprises approximately 90–
95% of cases in the diabetes syndrome (5). Chronic hyperglycemia
in diabetes leads to various metabolic, hormonal, and physiologic
alterations in the body, which further develop a number of sec-
ondary complications, which are responsible for major morbidity
and mortality (6).
These complications are wide ranging and are grouped into
“macrovascular complications” and “microvascular complica-
tions.” Macrovascular complications arise due to chronic hyper-
glycemia and associated cardiovascular risk factors affecting the
arteries that supply the heart, brain, and lower extremities. The
major macrovascular complications include accelerated cardio-
vascular disease (CVD) resulting in higher risk of coronary artery
disease (CAD), peripheral arterial disease, myocardial infarction
(MI), stroke, and limb amputation (7, 8). The complications
resulting from damage to small blood vessels are grouped as
microvascular complications. Persistent chronic hyperglycemia
resulting in development of diabetes-specific microvascular com-
plications in the retina, renal glomerulus, and peripheral nerves
are characteristic of all forms of diabetes. As a consequence of its
microvascular pathology, diabetes is the leading cause of blindness,
end-stage renal disease, and a variety of debilitating neuropathies
(7). Microvascular complications are classified into retinopathy,
nephropathy, and neuropathy. Other secondary complications
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associated with diabetes include diabetic foot ulcers (9), cardiomy-
opathy (10), depression (11), erectile dysfunction (12), increased
fracture risk and impaired bone healing (13), and cutaneous man-
ifestations (14). In this review, microvascular complications such
as retinopathy, nephropathy, and neuropathy are discussed and
the application of mesenchymal stromal cell therapy to the treat-
ment of multiple diabetic complications is examined in detail.
While each diabetic complication tends to be considered in iso-
lation, the EU Commission have recently funded a consortium,
REDDSTAR, which will focus on the use of mesenchymal stromal




DM is associated with development of several ocular complica-
tions and diabetic retinopathy (DR) is the most severe among these
ocular complications (15). It is the most frequent cause of new
cases of blindness among adults aged 20–74 years (16). As com-
pared to T2DM patients, individuals with T1DM are at higher risk
for development of more severe retinal complications and visual
loss. However, T2DM patients account for approximately 90% of
the population with DM, and they comprise a larger proportion
of those affected with DR (17). Clinically, there does not seen to
be differences in symptoms in type 1 or type 2 DM and nearly
all patients with long-term (20 years) DM will show some retinal
lesions (18, 19).
Diabetic retinopathy is clinically classified into non-
proliferative and proliferative disease stages. In non-proliferative
diabetic retinopathy (NPDR), there are only intraretinal microvas-
cular changes. The abnormalities due to non-proliferative
retinopathy include microaneurysms, small outpouchings from
retinal capillaries, altered retinal vascular permeability leading
to intraretinal abnormalities, and eventual retinal vessel closure.
Retinal vessel closure leads to non-perfusion, seen clinically as
increasing dot intraretinal hemorrhages, venous abnormalities,
and intraretinal microvascular abnormalities (15, 17). In this
initial stage of NPDR, most people do not notice any visual
impairment (8).
Proliferative diabetic retinopathy (PDR) involves the forma-
tion of new blood vessels on the retina or the optic disk. These new
abnormal blood vessels erupt through the surface of the retina and
proliferate into the vitreous cavity of the eye and can hemorrhage
into the vitreous, resulting in visual loss. Late in the course of the
disease, new blood vessels may form within the stroma of the iris
and may extend, with formation of fibrosis, into the structures that
drain the anterior chamber angle of the eye (15). Hyperglycemia
(20), hypertension (21), and dyslipidemia are considered as the
major risk factors for DR (22). Intensive glycemia control (16, 23)
and maintenance of blood pressure have greatly reduced the risk of
blindness from this disease, but retinopathy remains an important
complication in diabetic patients. In addition to glycemic con-
trol and blood pressure maintenance, other treatments include
injection of the steroid triamcinolone, and more recently, vas-
cular endothelial growth factor (VEGF) antagonists into the eye
(8), laser photocoagulation, and vitrectomy. These treatments are
helpful in reducing the vision loss but are invasive in manner and
can lead to loss of visual field, visual acuity loss, or risk of severe
postoperative visual loss.
DIABETIC NEPHROPATHY
Diabetic nephropathy is one of the leading causes of end-stage
renal failure in the western world (24). It is the major cause of
morbidity and mortality in T1DM patients and is becoming a seri-
ous clinical problem in T2DM patients (25). After presentation, the
initial changes in kidney include increased renal blood flow, hyper-
trophy, glomerular hyperfiltration, and hyperperfusion. These
early stage changes are reversible and are not considered as a
reliable indicator for the development of diabetic nephropa-
thy (26, 27). Persistent hyperglycemia for several years further
induces structural and cellular effects in the kidney. The significant
structural changes includes thickening of the glomerular base-
ment membrane, glomerular hypertrophy, increased extracellular
matrix accumulation (tubulointerstitial fibrosis) with mesangial
expansion, and modest expansion of the tubulointerstitium (25,
26, 28). High blood glucose induces cellular changes in various
types of cells present in the kidney. The major cellular abnor-
malities develop in glomerular epithelial cells (podocytes), which
includes broadening of podocyte foot processes with progressive
decrease in their number and density per glomerulus (29, 30).
Clinically, there is a decline in glomerular-filtration rate (GFR)
with progressive increase in urinary albumin excretion, and in
association with an increase in blood pressure, it ultimately leads to
end-stage renal failure (25). The earliest manifestation of diabetic
kidney disease can be detected by the presence of microalbu-
minuria, a state known as incipient diabetic nephropathy, where
there is presence of small amounts of albumin in the urine (30–
300 mg/day) (31). Microalbuminuria is considered as the earliest
marker and predictive of the development of proteinuria or overt
nephropathy, particularly in T1DM (25). It represents a poten-
tially reversible state of nephropathy and is sought in diabetic
management programs as a matter of routine. After the phase of
microalbuminuria, there is a continued increase in urinary protein
excretion with declining GFR. This results in the development of
Albustix-positive proteinuria and is known as overt nephropathy
or macroproteinuria. In diabetic patients with more than 5 years
of hyperglycemia, appearance of persistent albuminuria [albumin
excretion rate (AER)> 300 mg/24 h] without any urinary tract
infection (UTI), other renal diseases or heart diseases represents
diabetic nephropathy (32). If left untreated, uremia will supervene
and require referral to end-stage renal failure programs, such as
dialysis or transplantation.
Hypertension plays a critical role in the progression of diabetic
nephropathy. Controlling the blood pressure shows significant
renoprotective and antiproteinuric effects. In addition, lowering
blood pressure reduces albuminuria and attenuates the rate of
loss of GFR in both T1DM and T2DM patients (30, 33). The
major strategies currently used to reduce the risk of onset or
progressions of diabetic nephropathy are glycemic control along
with intensive management of systemic blood pressure. The major
strategy used to manage blood pressure is modification in renin–
angiotensin system (RAS) by means of angiotensin-converting
enzyme (ACE) inhibitors and/or angiotensin II (ANG II) receptor
antagonists (34, 35).
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DIABETIC NEUROPATHY
Diabetic peripheral neuropathy is one of the most frequent com-
plications of DM. Sixty-six percentage of people with T1DM and
59% of people with T2DM have objective evidence of periph-
eral neuropathy (36). The pathophysiology of diabetic neuropathy
(DN) remains complex and not fully elucidated. The consequences
of DN include impaired quality of life, pain, foot deformity,
neuropathic ulceration, and amputation.
The pivotal DCCT (Diabetes Control and Complications Trial)
supports the hypothesis that DN occurs as a result of high
glucose concentrations, however, subsequent research has impli-
cated several more biological mechanisms in the pathogenesis of
DN (37). Hyperglycemia results in oxidative stress and reactive
oxygen species (ROS) generation in addition to advance gly-
cation end product (AGE) production. This results in sensory,
motor, and autonomic nerve dysfunction (37). Vascular insuffi-
ciency, ischemia, hypoxia, dyslipidemia, metabolic syndrome, and
impaired insulin signaling are implicated in the development and
progression of DN (37). Pro-inflammatory cytokines contribute
to the pathogenesis of neuropathy and neuropathic pain. Injury
to peripheral nerves results from the production of cytokines that
originate from resident and recruited lymphocytes, macrophages,
neurons, and Schwann cells. Patients with both T1DM and T2DM
exhibit elevated blood levels of tumor necrosis factor-α (TNF-
α), and medications, which bind TNF-α improves nerve con-
duction velocity in rodents (37). The inflammatory cytokines
interleukin-2 and interleukin-6 are also increased as a result of
hyperglycemia, with patients suffering from painful DN display-
ing an increased level of high sensitivity C-reactive protein as
compared to non-painful DN (38, 39).
Diabetic neuropathy is characterized by a progressive neuronal
loss, dymyelination, and impaired nerve regeneration with ulti-
mately dysfunction of nerve fibers affecting both the autonomic
and somatic divisions of the nervous system (39). Neuropathic
ulceration, painful neuropathy, and autonomic dysfunction are the
consequence of DN. Distal symmetrical polyneuropathy is the pri-
mary cause of plantar ulceration. Nerve damage involves sensory,
motor,and autonomic nerves and subsequently the patient’s ability
to perceive pain, pressure, touch, and temperature is altered (40).
Motor neuropathy affects the small muscles of the foot and causes
weakness, atrophy, and deformity. The deformities include claw-
ing of the toes, prominent metatarsal heads with increased plantar
pressure and limited joint mobility. Autonomic neuropathy may
reduce sweating and increase the temperature of the foot, pre-
disposing to infection, and ulceration. The reduction in sweating
and increased temperature predispose to cracking of the skin and
consequent ulceration. Charcot’s neuroarthropathy is the result
of bony dislocation and collapse of the arch. Autonomic dys-
function is implicated with abnormal perfusion to foot bones.
The “rocker-bottom” deformity is prone to increased pressure and
ulceration (40).
Persistent neuropathic pain interferes significantly with qual-
ity of life, impairing sleep, and emotional well-being, and is a
significant causative factor for anxiety, loss of sleep, and non-
compliance with treatment. There is evidence suggesting an associ-
ation between neuropathic pain and depression, as for other types
of pain (41). A causative link has also been suggested between
DN and DR. In a rodent model of T2DM, it was shown that
the decrease in endothelial progenitor cell (EPC) release from
diabetic bone marrow was caused by bone marrow neuropathy
and that these changes preceded the development of DR (42).
The cornerstone of treatment of neuropathy is optimization of
glycemic control, thus improving symptoms and preventing pro-
gression of DN. Currently available pharmacological therapies are
frequently ineffective and are associated with multiple side-effects.
The first-line symptomatic treatments, which benefit DN include
antidepressants, e.g., serotonin–noradrenaline reuptake inhibitors
(e.g., duloxetine), tricyclic antidepressants (e.g., amitryptyline)
and anticonvulsants (e.g., gabapentin and pregabalin), and topical
lidocaine in addition to topical capsaicin cream provide symp-
tomatic relief. The addition of opiod analgesia may benefit in
refractory cases of painful DN (41, 43) and α-lipoeic acid has
demonstrated benefit in treatment of painful neuropathy (43).
Diabetic neuropathy results in an increased risk of foot ulcera-
tion. When patients present with a diabetic foot ulcer, assessment
of vascular supply is critical. If vascular supply is intact these
ulcers frequently represent neuropathic ulcers, and the treatment
includes debridement and off weight bearing. Non-healing ulcers
may be associated with infection and risk of amputation. If the eti-
ology of the ulcer is ischemic, blood flow will need to be restored,
or amputation may be necessary.
MESENCHYMAL STROMAL CELLS
The discovery and characterization of stem cells and their innate
properties has highlighted their potential as therapeutic agents in
regenerative medicine, in particular for the treatment of cardio-
vascular, musculoskeletal, neurodegenerative, and immunological
disorders, which heretofore have achieved only modest success
rates. Stem cells can be broadly characterized by their source and
tissue, they are typically generated from, and their differentiation
capacity in vitro. The current manuscript will focus on the poten-
tial use of MSCs in the treatment of microvascular and secondary
complications of DM.
MSC CLASSIFICATION
Mesenchymal stromal cells have been highlighted as a new emerg-
ing regenerative therapy in recent years. MSCs are progenitors of
all connective tissue cells and the International Society for Cellular
Therapy has defined three minimum requirements for classifica-
tion of cells as MSC; they must be plastic adherent in normal
culture conditions, differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro and express a defined population of cell
surface markers (44). MSCs have the capacity of self-renewal and
are multipotent, having the potential to differentiate into multiple
cell types such as adipocytes, chondrocytes, and osteoblasts, but
also differentiation into myocytes and neurons has been proposed
(45–49). They can be derived from many different organs and tis-
sues such as bone marrow, adipose tissue, nervous tissue, amniotic
fluid, umbilical cord, placenta, menstrual blood, and dental pulps
(50–53). MSCs are a subset of cells that express on their surface
CD54/CD102, CD166, CD49 as well as CD73 and CD90. They also
express CD44, CD105, whereas they do not express CD34, CD14,
CD45, CD11a/LFA-1, and CD31, which are surface markers of
hematopoietic cells and/or endothelial cells (44, 54). Although
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their differentiation capacity is less than other cell types such
as embryonic stem cells (ESC) or induced pluripotent stem cells
(iPSC), they still hold great promise for clinical applications having
been demonstrated to play a role in tissue repair and regeneration
in both pre-clinical and clinical studies, as they are able to migrate
and home to injured sites, where they act both by regenerating
tissues and by secreting trophic factors and paracrine mediators.
They also have remarkable immunosuppressive properties secret-
ing cytokines and immunomodulatory substances, and it is this
property that has received most attention in recent years (55–60).
MSCs IN TISSUE REPAIR
Mesenchymal stromal cells are believed to have an important role
in tissue repair (56). Upon tissue injury immune/inflammatory
cells, such as macrophages, neutrophils, CD4+ and CD8+ T cells,
and B cells are activated by factors from damaged cells and vessels,
and inflammatory molecules such as TNF α, IL-1β, free radi-
cals, and chemokines are released by phagocytes in response to
damaged cells and tissue. These immune cells and inflamma-
tory molecules together with fibroblasts and endothelial cells are
responsible for changes in the micro environment of the dam-
aged tissue that results in the recruitment and differentiation of
MSCs that can replace damaged tissue cells (61–63). In addition,
many factors including TNF-α, IL-1, IFN-γ, and hypoxia can stim-
ulate the release of growth factors from MSCs, such as epidermal
growth factor (EGF), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), transforming growth factor-β
(TGF-β), insulin growth factor-1 (IGF-1), and angiopoietin-1
(Ang-1),among others (64–67). These growth factors, in turn,pro-
mote the development of fibroblasts, endothelial cells, and tissue
progenitor cells, which carry out tissue regeneration and repair.
MSCs AS IMMUNE MODULATORS
Evidence in recent years has demonstrated that in addition to their
differentiation capacity and involvement in tissue repair, MSCs
have potent immunomodulatory functions. Through production
of soluble factors, MSCs can alter the secretion profile of den-
dritic cells (DCs) resulting in increased production of IL-10, an
anti-inflammatory cytokine, and decreased production of IFN-γ
and IL-12. MSCs can inhibit T cell production and increase the
number of CD4+CD25+FoxP3+ T-regulatory cells that suppress
the immune response (68, 69). MSCs can inhibit proliferation and
IgG secretion of B cells (70). Recent studies have shown that un-
stimulated MSCs are indeed incapable of immunosuppression;
they become potently immunosuppressive upon stimulation with
the supernatant of activated lymphocytes, or with combinations
of IFN-γ with TNF-α, IL-1α, or IL-1β. This observation revealed
that under certain circumstances, inflammatory cytokines can
actually become immunosuppressive (56). However, other stud-
ies have demonstrated that MSCs can be recognized by the host
immune system. In some experimental conditions, MSCs infused
into allogeneic, MHC-mismatched mice have been rejected (71,
72). Still their unique immunomodulatory properties made these
cells appropriate for both autologous and allogeneic transplant
investigations, as historically they have been considered poorly
immunogenic. For the same reason, they have been proposed as
a treatment for autoimmune diseases (73), and have been used
for the treatment of experimental models of rheumatoid arthri-
tis (RA), systemic lupus erythematosus (SLE), multiple sclerosis
(MS), and DM with its associated complications (74–78).
More recently, the immune privileged status of MSCs has
been questioned. Intracardiac allogeneic porcine MSCs elicit an
immune response despite their low immunogenic profile in vitro
(79). IV injection of allogeneic MSCs in rats lead to the forma-
tion of alloantibodies with the capacity to facilitate complement
mediated lysis, and this allo-MSC induce immune response was
sufficient to significantly reduce survival of subsequently injected
allogeneic MSCs (80). A recent review of the published literature in
the area indicated that the majority of studies documented some
cellular and humoral immune responses against donor antigens
following administration of non-manipulated, interferon acti-
vated,and differentiated allo-MSCs and the authors recommended
the anti-donor immune responses elicited by allo-MSCs be studied
in more detail (81).
MSCs AND GLYCEMIC CONTROL IN DM
An attractive feature of MSCs in the treatment of diabetic
microvascular complications is the reported ability of this cell
type to improve glycemic control, which can subsequently ben-
efit microvascular complications through systemic effects. Thus, it
is conceivable that MSCs can simultaneously treat hyperglycemia
and have a trophic effect on the underlying diabetic microvascular
complications. A variety of preclinical animal models have shown
a beneficial effect of MSC transplantation on glycemia through a
direct effect of differentiation to cells capable of producing insulin
(less likely), or an indirect effect of secretion of immunomodula-
tors, which prevent endogenous T cells from eliciting pancreatic
β-cell destruction, or other as yet unknown factors, which influ-
ence insulin secretion or action. Initial studies demonstrated that
bone marrow cells had the capacity to differentiate into insulin-
producing cells, and aggregates of these cells when transplanted
into the kidney capsule of diabetic mice could lower blood glucose
and maintain near normal glucose levels for 90 days. Graft removal
resulted in rapid relapse and death of the experimental animals
(82). In an animal model of T1DM where rodents were induced
to develop diabetes through streptozotocin (STZ), MSC were able
to differentiate into insulin-producing cells, releasing insulin in a
glucose dependant manner and improving diabetic symptoms (83,
84). These insulin-producing cells express multiple genes related
to the development or function of pancreatic beta cells, including
high expression of pancreatic and duodenal homeobox 1, insulin,
and glucagon (84) and were able to release insulin in a glucose-
dependent manner that led to amelioration of diabetic conditions
in STZ-treated nude mice (84, 85). Transplantation of undifferen-
tiated MSCs into STZ-induced diabetes in C57Bl/6 mice induced
normoglycemia and reversed glycosuria. This was accompanied
by improved renal function and histological evidence of regener-
ation of normal beta pancreatic islets (86). In non-obese diabetic
NOD mice, the injection of MSC reduced the capacity of diabeto-
genic T cells to infiltrate pancreatic islets thus preventing β-cell
destruction (87). An additional cooperative action of MSC’s on
co-transplantation with pancreatic islets results in improved graft
morphology and improved revascularization indicating that pos-
sible trophic factors secreted by MSCs are aiding islet engraftment
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(88). Furthermore, multiple IV infusions of MSCs to a rodent
model of T2DM resulted in normalization of blood glucose levels,
which remained stable for 9 weeks after infusion. Serum concen-
trations of insulin and C-peptide were dramatically increased after
MSC infusion and damaged pancreatic islets were restored to near
normal with the ratio of insulin-positive cells per islet achieving
near normal levels (89).
MSC-BASED THERAPIES FOR DIABETIC MICROVASCULAR
COMPLICATIONS
The worldwide increase in the prevalence of DM has highlighted
the need for increased research efforts into treatment options for
both the disease itself and its associated complications. Of partic-
ular concern is the increasing prevalence of diabetes affecting ado-
lescents and young adults (90) promoting an earlier development
of chronic illness caused by hyperglycemia, which is characterized
by microvascular complications (retinopathy, nephropathy, and
neuropathy) prolonged/incomplete wound healing, cardiomyopa-
thy, or impaired bone repair. Both T1DM and T2DM patients can
develop secondary complications, the risk of which is related to the
duration of diabetes and the degree of glycemic control (91). This
has prompted investigators not only to analyze the effect of stem
cells and in particular MSC transplantation on glycemic control
but also to assess the beneficial effects of MSCs on the resultant
secondary diabetic complications.
MSC-BASED THERAPIES FOR DIABETIC RETINOPATHY
A variety of animal models have been used to investigate DR (92)
and these species do develop at least the early stages of retinopathy,
including retinal capillary degeneration. The severity of disease
in these models does increase with diabetes duration, however
symptoms are still considered mild compared to long-term DR
symptoms seen in patients, partly due to the limited lifespan of
these laboratory animal models. Thus, the current animal mod-
els of DR are not considered fully reflective of human DR (93).
Investigators have turned their attention to non-diabetic mod-
els of retinal neovascularization caused by branch vein occlusion,
oxygen-induced retinopathy (94), or overexpression of growth fac-
tors such as VEGF (95) or IGF-1 (96). Most studies investigating
cell effects of DR have involved EPC and those patients with ear-
lier stages of disease (NPDR) exhibit reduced number of EPC
compared to higher levels in patients with PDR (97, 98), most
probably due to inflammatory reactions in damaged tissue and
increased mobilization of EPC from the bone marrow in later
stages of disease.
To date, there are no clinical studies evaluating the effect
of adult stem cells in DR, however, animal models do give an
indication of possible mechanisms of vascular repair. In studies
carried out on ischemic retinal injury, adult stem cells (hematopoi-
etic/mesenchymal) participate in retinal repair, homing into dam-
aged areas, and differentiating into endothelial cells, microglia,
and astrocytes (99–102). It has been shown that bone marrow-
derived MSCs can differentiate into retinal cells and endothelial
cells and rescue photoreceptors in the diseased retina (100, 103,
104). Animal studies have demonstrated that subretinal transplan-
tation of MSCs delays retinal degeneration and preserves retinal
function through a trophic response (105). In a rat model of
retinitis pigmentosa, IV administration of BM MSCs prevented
photoreceptor loss and preserved visual function (106). In an STZ
rodent model of DR, intravenous injection of adipose-derived
MSC resulted in a significant reduction in blood glucose levels
in treated rats 1 week after transplantation, an improvement in
the integrity of the blood–retinal barrier and evidence of the
presence of donor cells in the retinas of treated rats and dif-
ferentiation into photoreceptor cells and astrocytes (101). It has
also been demonstrated that a single intravitreal injection of pla-
cental derived MSCs results in a significant decrease in retinal
apoptosis in rodents rendered diabetic by a single STZ injection,
by virtue of increased intravitreal, and retinal concentrations of
neuroprotective growth factors (107).
However, there are questions as to the therapeutic value of
angiogenic cell-based strategies in long-term PDR as they may
risk worsening the aberrant reactive neovascularization in PDR
that follows ischemic retinal injuries. To this end, some investiga-
tors have suggested a combination therapeutic approach of MSC
administration with the HMG-CoA reductase inhibitor atorvas-
tatin, which may prevent excess VEGF production by MSCs under
hypoxic conditions and have the potential to improve viability and
homing of the transplanted MSCs (108).
MSC-BASED THERAPIES FOR DIABETIC NEPHROPATHY
Animal studies have indicated that MSCs are successful candi-
date cell therapies for both the prevention and treatment of
diabetic nephropathy. In studies where immune compromised
NOD/SCID mice received systemic administration of human
MSC’s or C57Bl/6 mice received murine MSC’s after induction of
diabetes by STZ, results indicated that hyperglycemia was reversed
and nephropathy was either prevented or repaired (78, 86). The
result of systemic administration of MSCs in these studies was a
reduction in blood glucose with an associated improvement of kid-
ney function. After an intracardiac infusion of MSC, 11% of these
cells engrafted into the kidneys, where they differentiated into
endothelial cells. The engraftment of hMSCs into kidney was asso-
ciated with improvements in glomerular morphology, a decrease
in mesangial thickening, and a decrease in macrophage infiltration
(78). It is important to confirm whether these beneficial effects on
nephropathy were due to improvement in glycemia or a direct
effect on the kidney. MSCs also had the ability to slow the progres-
sion of diabetic nephropathy through mechanisms independent
from glycemic control as in a subsequent study comparing MSC-
treated versus untreated DM mice, MSC-treated mice remained
hyperglycemic but exhibited basal levels of albuminuria and very
minor tubular dilation (109).
The effect of MSC administration on glucose levels and kid-
ney function has also been assessed in other rodent models. In
studies where diabetes was induced in Sprague-Dawley rats by a
single IP injection of STZ, introcardiac infusion of bone marrow
MSC resulted in a decrease in blood glucose, Alb/Cr ratio and
renal mass index compared to control (110). The renoprotective
effect of human umbilical cord derived MSCs has been exam-
ined in a rodent model of DM. Four weeks after STZ injection,
hUMB cord derived MSCs prevented diabetic renal injury (except
renal and glomerular hypertrophy) without a significant effect on
blood glucose (111, 112) indicating that paracrine factors may be
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involved in the protection. The injection of hUMB cord MSCs after
induction of hyperglycemia effectively prevented proteinuria and
increased fractional mesangial area albeit with a low level of kidney
engraftment (112). Autologous transplantation of adipose-derived
MSCs minimized pathological alterations, reduced oxidative dam-
age and suppressed the renal expression of pro-inflammatory
cytokines in a rodent STZ model of diabetic nephropathy (113).
Adipose MSC implantation significantly alleviated all indices of
metabolic dysfunction when compared to controls including a
reduction in blood glucose. Expression of MAPK signaling path-
way molecules (p-p38, p-ERK and p-JNK) was also reduced in
MSC-treated rodent renal tissues leading the authors to suggest
that the positive therapeutic effect of adipose-derived MSCs on
diabetic kidneys could be due to suppression of inflammatory
response and oxidative stress (113).
More recent investigations have expanded mechanism of action
studies to examine the effects of either allogeneic (114) or syn-
geneic (115) MSC administration on glomerular podocyte injury.
Human adipose-derived MSCs are able to prevent high glucose
induced podocytic apoptosis and injury mainly by secreting sol-
uble EGF (114). Administration of bone marrow-derived MSCs
via the left renal artery of diabetic rats prevented the development
of albuminuria and the loss of podocytes and resulted in a sup-
pressed increase in kidney weight, kidney to body weight index,
creatinine clearance rate, and urinary albumin to creatinine ratio,
although the treatment had no effect on blood glucose or body
weight levels (115). There was evidence of targeted engraftment
of MSCs in the renal tissue as intra-arterial injection led to 20%
of glomeruli containing EGFP+ cells at 24 h with no evidence of
labeled cells in the lung, liver, or spleen. However analysis after
60 days indicated a low level of persistent engraftment as only 3%
of glomeruli subsequently retained labeled cells. The authors sug-
gested this low level of engraftment suggested a paracrine mode
of action with MSCs exerting their beneficial effects by increasing
expression of the podocyte survival factor BMP-7 (115). Modi-
fication of the expression of immunomodulators has also been
proposed as a possible mechanism for the renoprotective effects
of MSCs. In a rodent model of DM and diabetic nephropathy,
MSC treatment ameliorated diabetic nephropathy via inhibition
of MCP-1 expression by secreting HCP, thus reducing macrophage
infiltration and down-regulating Il-1β, IL-6, and TNF-α expres-
sion in the renal tissue of diabetic rates (116). Others have found
beneficial effects of a targeted treatment of MSC administration,
using an ultrasound-targeted microbubble destruction (UTMD)
technique. Autologous administration of MSCs to diabetic rats in
combination with UTMD reduced blood glucose levels, decreased
urinary AERs, prevented renal damage, and enhanced homing of
MSCs to damaged renal tissue (117).
These studies indicated that MSC cell therapy of diabetic
nephropathy may involve individual or combinatorial effects
of various renoprotective processes, e.g., differentiation of cells
and regeneration, immune modulation/protection, and/or con-
trol of hyperglycemia but the complete derivation of the exact
mechanisms of action have yet to be elucidated. As the avail-
able animal models only mimic the earlier stages of diabetic
kidney disease the impact of MSC transplantation on individ-
uals exhibiting advanced signs of diabetic nephropathy such as
nodular glomeruloschlerosis remain unproven. At present there
is one actively recruiting clinical study registered at ClinicalTri-
als.Gov1 investigating the safety and efficacy of MSCs in diabetic
nephropathy.
MSC-BASED THERAPIES FOR DIABETIC NEUROPATHY
Mesenchymal stromal cells offer a novel therapeutic option to treat
DN. MSCs modulate the central nervous system injured envi-
ronment and promote repair as they secrete anti-inflammatory,
anti-apoptotic molecules, and trophic factors to support axonal
growth, immunomodulation, angiogenesis, remyelination, and
protection from apoptotic cell death (118). MSCs are known
to support angiogenesis, which augments the microcirculation
supporting peripheral nerves. This impaired vascular supply has
been implicated in the etiology of DN. This pro-angiogenic ben-
efit occurs mostly through a paracrine effect. Transplanted MSCs
not only directly differentiate into neurons and endothelial cells
on administration, but also secrete a broad range of biologically
active factors, generally referred to as the MSC secretome. Secre-
tome analysis of MSCs demonstrates that increased concentrations
of FGF, VEGF-A, and nerve growth factor are produced from
MSCs (119, 120). These factors are central to nerve and vascular
tissue health.
Mesenchymal stromal cells have demonstrated benefit in other
inflammatory and ischemic conditions. The therapeutic benefit
of MSCs in these instances is now believed to be by short-term
(hours to days) paracrine and juxtacrine modulation of immune
responses rather than by long-term (days to months) engraftment
of the MSCs to the injured site (38). These exists a paucity of data
on the effect of MSCs on the treatment of DN at the clinical level,
however, pre-clinical data has revealed beneficial effects of MSC
administration. In a rodent model of DM, intramuscular injec-
tion of MSCs resulted in amelioration of the symptoms of DN.
Transplantation of MSCs improved hypoalgesia, delayed motor
nerve conduction velocity (MNCV), reduced sciatic nerve blood
flow (SNBF), and decreased axonal circularity in diabetic nerves of
treated rats. The authors indicated that this was most likely due to
a paracrine effect as the MSCs were not incorporated into the tis-
sue structures of recipient animals (118). In an STZ-induced DN
mouse model, bone marrow-derived MSCs significantly increased
expression of neurotrophic factors and ameliorated nerve conduc-
tion velocity in diabetic mice (121). Subsequent improvements
in MSC cell preparations to generate anti-inflammatory MSC2
populations resulted in significant improvements in behavioral
assays in a mouse mode of painful diabetic peripheral neuropathy
(pDPN) and mice treated with these MSC2 cells had decreased
serum levels of pro-inflammatory cytokines (38). MSC admin-
istration also promoted increased density of sympathetic and
parasympathetic nerves in the ventricular myocardium of diabetic
rats, increased the ratio of parasympathetic to sympathetic nerve
fibers and resulted in the suppression of ventricular arrhythmia
inducibility (122).
Clinical investigations have recognized the potential benefits of
MSC therapy in the treatment of painful disease such as degen-
erative disk disease and osteoarthritis (123), however, there is
1http://clinicaltrials.gov/, accessed 30.04.14
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no human data on the benefit of MSC administration for the
treatment of DN. The mode of administration, dose, and MSC
subpopulation, which is the most efficacious, is yet to be deter-
mined. Nonetheless, in light of the exciting preclinical evidence
of the benefit of MSCs on immunomodulation, angiogenesis, and
neurogenesis coupled with the emerging evidence on the glucose
lowering effect of MSC therapy, this cell-based treatment may syn-
ergistically improve nerve function and alleviate the symptoms
and clinical consequences of DN. This will potentially reduce the
burden of neuropathic ulceration, pain, and impaired quality of
life associated with DN. MSC treatment offers potential benefit in
humans with DN, which is currently sub-optimally managed with
contemporary treatment strategies.
MSC-BASED THERAPIES FOR OTHER DIABETIC
COMPLICATIONS
MSC-BASED THERAPIES FOR DIABETIC WOUND HEALING
Effective wound healing is an orchestrated response involving
angiogenesis, enhanced cellularity, re-epithelialization, and glan-
dularization, and this is indicative of cutaneous regeneration
although the specific cell types involved in each event are not yet
known (124). Prolonged and incomplete wound healing, caused
by compromised angiogenesis, diminished cell recruitment, lack
of growth factors, and impaired formation of collagen matrix is
another common complication of DM. It has been demonstrated
that generally the number of MSC increases considerably in the
site of an injury, and that after a vascular trauma a rapid mobi-
lization to the injured site of EPC also takes place. Recent studies
suggest that MSC and EPC are a significant proportion of the non-
inflammatory cells that migrate to the skin to promote wound
healing (125).
A variety of pre-clinical studies have demonstrated a beneficial
effect of MSC administration on wound healing and ulceration in
diabetic animals albeit with slightly different mechanisms depen-
dant on autologous or allogeneic administration of progenitor
cells. Administration of murine diabetic MSCs inhibited angio-
genesis but promoted wound healing in diabetic mice (126) while
healthy murine bone marrow-derived MSCs or their conditioned
medium were sufficient to promote would healing through dif-
ferentiation and angiogenesis (127, 128). Bone marrow-derived
MSC have also been shown to improve wound healing in dia-
betic rats following topical or systemic administration (129). After
IV administration of MSCs, diabetic wounds showed significantly
increased collagen levels in addition to significantly increased lev-
els of growth factors (e.g., EGF, PDGF, and VEGF) that resulted
in repair of injured tissue and successful would healing by means
of increased secretion of chemokines and increased neovascular-
ization (129). MSCs have also been identified as having direct
effects on wound healing through differentiation and regenera-
tion of damaged tissue (127, 130). MSCs promoted angiogenesis
through enhanced capillary density and the progenitor cells them-
selves settled in the newly formed dermis (127, 128, 130). The
therapeutic efficacy of bone marrow-derived MSCs to heal fas-
cial and cutaneous wounds was investigated in Sprague-Dawley
rats (131). Systemic administration of single or multiple doses of
syngeneic MSCs resulted in a significant increase in wound burst-
ing strength 7 and 14 days post wounding. Local administration
of MSCs also promoted wound healing and the authors found
that allogeneic MSCs were as efficient as syngeneic MSCs in
promoting wound healing (131). Local administration of MSCs
pre-stimulated with EGF restored blood flow and vasculogenesis
in an ischemic hind-limb of type 2 diabetic db/db mice (132).
Interestingly, the intradermal injection of adipose-derived MSCs
to a dorsal rodent wound improved would healing when com-
pared to control rats but this occurred without a significant effect
on angiogenesis or fibroblast accumulation, which lead the authors
to suggest the beneficial effect observed was most probably due to
the secretion of protective and anti-apoptotic factors such as VEGF
and HGF (133).
As indicated above, MSCs are known to promote angiogen-
esis with improved cutaneous wound healing and biomaterials
may increase viability of cells and thus enhance therapeutic effi-
cacy. We previously hypothesized that topically applied allogeneic
MSCs wound improve wound healing by augmenting angiogene-
sis and tested this hypothesis in an alloxan-induced diabetic rabbit
ear ulcer model (134) where allogeneic MSCs were seeded in a
collagen scaffold and were then applied to a full thickness cuta-
neous wound on the diabetic rabbit ear. Three doses of MSCs were
analyzed and percentage wound closure and angiogenesis were
assessed 1 week following cell treatment. Topical application of
1× 106 MSCs showed increased percentage wound closure com-
pared to lower doses and resulted in increased angiogenesis when
compared to untreated wounds. Following on from this study, we
are currently investigating the use of a novel antibody (ORB1)
that can be used to FACS-isolate ORB1+ MSC from human bone
marrow with enhanced purity ratios. In this model, we are inves-
tigating the effect of xenotransplantation of human MSCs in a
collagen matrix to the same alloxan-induced diabetic rabbit ear
ulcer model.
Clinical investigations are already underway investigating the
effect of local administration of MSCs to chronic non-healing
wounds and there is significant interest in the clinical translation of
MSC-based therapies to promote dermal regeneration. MSCs are
readily available from commercial allogeneic sources or as autol-
ogous sources that can be harvested at the point of care from
various tissues. Initial clinical studies centered on the beneficial
effects of bone marrow aspirate (BMA) or MSC administration
on chronic wounds but in the case of diabetes they were often sin-
gle case reports. Locally applied BMA to a chronic neuro-ischemic
wound in a T2DM patient resulted in restored angiogenesis and
improved wound healing (135). The combination of the appli-
cation of bone marrow-derived MSCs with a fibroblast collagen
membrane resulted in complete wound closure of a 25-year open
wound foot ulcer within 4 weeks (136). Topical administration
of autologous bone marrow MSCs to a diabetic patient with an
ischemia-induced foot ulcer also demonstrated positive effects on
wound healing (137).
In the light of the extensive preclinical data demonstrating the
beneficial effects of MSCs in the promotion of dermal wound
healing, the clinical translation of these cells remains fairly limited
(with small patient populations), but initial clinical studies are
just as promising. Autologous culture-expanded bone marrow-
derived MSCs applied via a fibrin spray to 13 patients with acute
and chronic wounds demonstrated that MSCs migrated into the
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wound and appeared to stimulate elastin expression resulting in
the synthesis of a dermal matrix with improved ECM composition.
Acute wounds healed within 8 weeks and chronic year long lower
extremity wounds significantly decreased or healed within 16–
20 weeks (130). Autologous bone marrow-derived MSCs seeded
on a collagen sponge were effective to facilitate the closure of
ulcerated wounds (138). This study included 20 patients with non-
healing wounds of various etiologies and the authors reported
nearly complete healing in 18 patients with vascular regeneration
of native tissue evident by immunohistochemical analysis. The
effects of the administration of autologous bone marrow-derived
MSCs to non-healing lower extremity wounds was investigated
in a level one randomized controlled trial of 24 patients whereby
MSC therapy significantly reduced wound size and improved clin-
ical parameters (139). All of these studies have confirmed the safe
therapeutic benefit of MSCs in the clinical setting of wound heal-
ing. As regards to larger clinical studies of wound healing in DM
patients only four studies are registered at ClinicalTrials.Gov1 one
has unknown status and one is not yet recruiting. Of the two com-
pleted studies, one had results available. In this clinical study, bone
marrow-derived stem cells were applied to treat ischemia-induced
chronic foot ulcers in 22 diabetic patients and 18 patients exhibited
wound healing after 45 weeks, with improvements in microvascu-
larization detected in some but not all patients (140). Thus, while a
variety of pre-clinical and clinical studies have demonstrated very
beneficial effects of MSCs in relation to wound healing in diabetic
and other patients, larger phase one and two studies are needed to
confirm the value of MSCs in wound therapy.
MSC-BASED THERAPIES FOR DIABETIC CARDIOMYOPATHY
Both types of DM increase the progression of atherosclerosis and
the development of macrovascular complications, with clinical
manifestations such as CAD, peripheral artery disease (PAD), and
stroke, and these patients have a two to fourfold increased risk
of fatal MI (141, 142). Development of ventricular dysfunction
in patients with DM in the absence of CAD, valvular heart dis-
ease or hypertension is defined as diabetic cardiomyopathy (DC)
(143). DC caused by hyperglycemia causes changes in the diabetic
myocardium such as hypertrophy, apoptosis of cardiomyocytes,
and abnormal myocardial matrix deposition. Specifically in DC,
there are changes in the activity of matrix metalloproteases MMP-2
and MMP-9. Reduced MMP-2 activity results in increased collagen
accumulation and increased activity of proapoptotic MMP-9 and
subsequent cell apoptosis, capillary density reduction, and poor
myocardial perfusion. Other pathological consequences include
microcirculatory defects, and interstitial fibrosis (143–145).
The application of MSCs in the treatment of DC (in addition to
other CVDs) has received much attention in preclinical and clinical
environs in recent years and MSCs do offer promising treatments
due to their direct differentiation to cardiomyocytes but also due
to the secretion of potent trophic and paracrine mediators, capa-
ble of inducing cardioregeneration and cardioprotection. This was
elegantly demonstrated in studies of rats with type 1 DM. Intra-
venous administration (into the femoral vein) of bone marrow-
derived MSCs to rats with DC resulted in improved cardiac func-
tion of the treated animals through increased angiogenesis and
attenuated cardiac remodeling. Transplanted MSCs differentiated
into cardiomyocytes and improved angiogenesis and myogenesis.
MMP2 activity increased, MMP-9 activity decreased, and there
was reduced collagen content in the diabetic myocardium (146).
Intramyocardial transplantation of MSC was found to have a pro-
tective effect on the diabetic myocardium and DC, and anoxic pre-
conditioning (AP) of MSCs was found to enhance this protective
effect. In a rodent model of DC, 2 weeks after MSC administration,
MSC and AP-MSC groups increased the fractional shortening of
the diabetic heart. AP-MSC groups increased myocardial capillary
density, attenuated myocardial fibrosis, and inhibited cardiac cell
apoptosis (147).
Pre-conditioning of diabetic MSCs with medium from car-
diomyocytes exposed to oxidative stress and high glucose (HG/H-
CCM medium) also had a beneficial effect on cardiac tissue
regeneration. In a mouse model of DM, autologous MSCs pre-
conditioned with HG/H-CCM exhibited upregulated gene expres-
sion of angiogenic and cardiac markers. When these cells were
implanted by intramyocardial injection into the hearts of STZ-
induced diabetic mice (approximately 0.1× 106 MSC/animal),
cardiac function was markedly improved. Pre-conditioned MSCs
demonstrated increased homing ability, increased expression of
angiogenic and cardiac markers and paracrine mediators, such as
IGF-1, HGH, SDF-1, and FGF-2. Four weeks after transplanta-
tion reduced fibrosis, apoptosis, and increased angiogenesis was
observed in the mouse diabetic hearts (148). This effect was not
seen, however, in a mouse model of obesity-induced DC. IV
administration of allogeneic bone marrow-derived MSCs with a
single dose of 0.5× 106 or three consecutive monthly doses of
0.5× 106 MSCs did not result in improved cardiac function when
assessed 4 months later but rather has a neutral effect on DC. The
observed effects may be as a result of the route, time, and dose used
but possibly also to issues with efficient homing and engraftment
of the tail vein administered cells (149).
More positive results were seen in a rodent model of dilated car-
diomyopathy (DCM). MSC transplantation (5× 106 cells by injec-
tion into the rat myocardium) resulted in induction of myogenesis
and angiogenesis and secretion of large amounts of angiogenic
and anti-apoptotic factors (VEGF, HGF, adrenomedulin (AM),
and IGF-1). A comparison of conditioned medium from MSC
versus mononuclear cells MNC revealed MSCs secreted fourfold
more VEGF than MNCs. Transplanted MSCs differentiated into
cardiomyocytes, vascular endothelial cells, and smooth muscle
cells and there was improvement in cardiac function, inhibition
of ventricular remodeling, and a decrease in collagen volume in
the myocardium with a reduction in myocardial fibrosis when
compared to untreated tissue (150).
MSCs administration can also result in improvements in car-
diac function through secretion of paracrine mediators, such as
Bcl-2, HSP20, and hypoxia-regulated heme oxygenase-1, hypoxic
Akt-regulated stem cell factor, VEGF, HGF among others (151).
Recent evidence strongly suggests these factors affect remodeling,
regeneration, and neovascularization leading to improvements in
myocardium contractility and viability (54). Release of trophic
mediators by MSCs had also been suggested. Intramuscular deliv-
ery of MSCs resulted in improved ventricular function in a hamster
heart failure model with enhancement of the density of capillaries
and myocytes and a reduction in apoptosis and fibrosis (152).
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Based on promising pre-clinical studies, clinical trials have been
initiated investigating the effects of MSC transplantation on MI
and ischemic cardiomyopathy. Intracoronary administration of
autologous BM MSCs to 34 patients with subacute MI demon-
strated improvements in perfusion defects and left ventricular
chamber size and ejection fraction (EF) 3 months after administra-
tion (153). Similarly, 3 months after intravenous administration
of allogeneic BM MSCs to patients with acute MI, beneficial
effects such as improved pulmonary function, left ventricular
EF, and reduced ventricular tachycardia were observed in the
hMSC treatment groups. This study also provided important
safety data for the administration of allogeneic MSCs to human
populations (154). Furthermore, with intramyocardial injection
of BM MSCs beneficial effects have been noted in clinical tri-
als of ischemic cardiomyopathy. Three months after treatment,
autologous bone marrow MSCs and MNCs cell therapy groups
exhibited functional recovery in scarred myocardium and reverse
modeling of the LV chamber though the number of patients
in this study was low (n= 8) (155). A variety of other clinical
trials are underway investigating effects of MSCs on heart dis-
ease (156) and various possible mechanisms of MSC-mediated
cardiac improvement have been suggested including transdiffer-
entiation, paracrine signaling, somatic reprograming, and direct
electrophysical coupling (157) but precise delineation of the
functional consequences of MSC administration remains to be
elucidated.
MSC-BASED THERAPIES FOR DIABETIC BONE FRACTURES
Research over the past few decades has accumulated to indicate that
diabetes adversely affects bone quantity and/or quality, and that
these skeletal changes, in combination with the microangiopathic
complications of diabetes, may increase the risk of bone fracture
(158). A systematic review of six patient studies has identified
that indeed there is a six to sevenfold increased risk of hip frac-
ture in T1DM rather than non-diabetic individuals with increased
risk in other sites too such as spine, proximal humerus and foot
(159, 160). With T2DM inconsistent results have been reported in
relation to the disease and fracture risk however there are more
consistent reports in the literature in relation to the incidence of
hip fracture. The risk of hip fracture was increased by 18% in men
and 11% in women with DM and in particular T2DM in a large
scale Canadian study of diabetic and age-matched non-diabetic
controls (161). Furthermore in a recent large scale retrospective
analysis of 16 independent studies, there was significant positive
associations between the incidence of any non-vertebral fracture,
hip fractures, and foot fracture and T2DM (162).
Proposed mechanisms underlying the increased fracture risk in
DM include changes in bone mass as a result of hyperglycemia with
low bone turnover observed in patients with T1DM and T2DM
(158) and changes in bone quality. Rodent models and initial clin-
ical studies suggest DM results in a general weakening or fragility
of bone structure that does not necessarily significantly affect elas-
ticity, strength, or fracture toughness (163–165) but may be due to
accumulation of advanced glycation end-products (AGEs) within
bone collagen (166). Complications of T2DM including retinopa-
thy and autonomic dysfunction may contribute to bone fracture
by increasing fall risk (167).
Bone regeneration is reliant on a close spatial and temporal
connection between blood vessels and bone cells thus angiogenesis
plays a crucial role in skeletal development and bone fracture repair
(168). The most critical factor in fracture union is blood supply
to the fracture site, which is usually impaired in patients with DM
(169) thus diabetic patients are more prone to non-union bone
fractures. Current protocols to repair bone defects include autol-
ogous or allogeneic bone grafts or implants (e.g., polymeric or
metallic), however, there are problems with the above approaches
including lack of adequate supply, disease transmission, rejection,
cost, and the inability to integrate with the surrounding host tissue.
For these reasons combination therapies of stem cells in scaf-
folds with various growth factors to promote angiogenesis and
osteogenesis are being investigated as a tool for bone regeneration
(168). Bone healing assisted by MSC can be a powerful clinical
tool for bone regeneration because of their ability to differenti-
ate directly into osteoblasts (170, 171) in addition to secretion of
pro-angiogenic factors such as VEGF.
To this end, combined delivery of pro-osteogenic factor BMP-
4 and pro-angiogenic VEGF in a poly (lactic-co-glycolic acid)
scaffold with human bone marrow-derived MSCs resulted in a
significant increase in the quantity of regenerated bone com-
pared with single or dual combinations of these factors, when
measured by DXA, X-ray and histomorphometric analysis (172).
When MSC-titanium implant complex were implanted in the
right tibia of type 2 diabetic rats, bone volume ratio and trabec-
ular thickness increased significantly and trabecular separation
decreased significantly after 8 weeks when the MSC-implant com-
plexes were compared to titanium implants alone. Histological
analysis indicated a greater amount of bone tissue formed around
the MSC-implant complexes with a higher bone implant contact
rate (BIC) than titanium alone (173). In a rat model of DM, even
the use of conditioned medium from MSCs was sufficient to pro-
mote fracture healing. MSC derived conditioned medium has been
shown to contain significantly higher levels of angiogenic factors
such asVEGF and IL-6. When gelatine sponges were soaked in con-
ditioned medium from MSCs and were then implanted into fibular
defects in a rodent model of DM, the conditioned medium was
sufficient to enhance bone growth and fracture healing compared
to control media (169).
The use of allogeneic MSCs to repair non-diabetic bone defects
in other rodent or canine models has also been investigated. In
rats with a femoral segmental defect, BMP-2-engineered allogeneic
MSCs repaired bone defects to the same degree as in rats treated
with BMP-2-engineered autologous MSCs. It was also demon-
strated that allogeneic gene-transferred MSCs are directly involved
in bone repair, in addition to acting as gene deliverers (174). Use of
allogeneic MSCs loaded on hydroxyapatite–tricalcium phosphate
implants enhanced the repair of a critical-sized segmental defect in
dog femurs without the use of immunosuppressive therapy (175).
In this case, no adverse immune response was detected. Further-
more, the lack of detected immunogenicity of allogeneic MSCs in
these orthopedic studies is an advantage for the clinical application
of pre-constructed tissue-engineered bone.
There is a lack of clinical data on the use of MSCs in the treat-
ment of diabetic non-union bone fractures, however, use of the
cells has been investigated for the treatment of other bone diseases
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albeit for small numbers of patients. In a study of 6 children suf-
fering from Osteogenesis imperfect (OI), systemic administration
of allogeneic MSCs resulted in acceleration of bone growth for
five of the six children (176). In children with hypophosphata-
sia, a rare heritable metabolic bone disease, bone marrow trans-
plants resulted in marked improved in clinical symptoms, which
continued several years after transplant administration although
reported studies were single case reports (177, 178).
MSCs AND THE REDDSTAR PROJECT
Poor control of blood glucose in DM levels leads to a num-
ber of diabetic complications as indicated previously, including:
retinopathy, nephropathy, cardiomyopathy, neuropathy, impaired
bone repair, and wound ulceration. At present, there are few ther-
apeutic options available to control initiation and progression of
diabetic complications and they continue to present challenging
disease management issues for clinicians. We have recently received
funding from an EU FP7-HEALTH-2012-INNOVATION-1 Grant
for a 3-year multicenter multidisciplinary investigation of the use
of MSCs in the treatment of DM (REDDSTAR, Repair of Dia-
betic Damage by Stromal Cell Administration). The REDDSTAR
Project2 will comprehensively examine if MSC/Stromal Stem Cells
(SSC) can safely control glycemia and alleviate damage caused
by six diabetic complications. The REDDSTAR consortium is a
network of diabetes specialists, regenerative medicine researchers,
biotech industrialists, and clinicians, supported by an experienced
project management team (Figure 1).
REDDSTAR partner Orbsen Therapeutics has identified a novel
antibody (ORB1) that can be used to prospectively isolate ORB1+
SSC from human bone marrow with enhanced purity ratios. This
new SSC platform technology is a radical improvement in terms of
cell purity and compliance with upcoming regulations and RED-
DSTAR will investigate the efficacy and mechanism of action of
this second-generation SSC in six major diabetic complications.
The first 18 months of the project will involve investigating the
pre-clinical safety and efficiency of SSC in resolving the six com-
plications arising from diabetes. The impact of SSC upon blood
glucose levels will also be tested. The second 18 months of the
project will involve examining the mechanism of action of how
SSC improve diabetic complications. REDDSTAR partners will
also submit a clinical trial application to the Danish Medicines
Agency to undertake clinical trials on diabetic patients with the
complication(s) that yield the best results in phase 1 of the project,
thus the REDDSTAR project incorporates both preclinical and
clinical development of a novel stem cell therapy within a relatively
short timeframe.
CHALLENGES AND CONSIDERATIONS IN MSC-BASED
THERAPIES AND FUTURE PROSPECTS
The application of the use to MSCs to treat microvascular and
other common secondary complications of DM has been exten-
sively investigated in pre-clinical animal models in recent years
and the majority of reports indicate positive effects on diabetic
complications. Despite this, there are significant challenges to be
2http://www.reddstar.eu
FIGURE 1 |The REDDSTAR project (www.reddstar.eu). The REDDSTAR
(Repair of Diabetic Damage by Stromal Cell Administration) consortium is a
multinational collaboration involving academic groups in the EU with
expertise in the vascular damage resulting from complications of DM. The
aim of the REDDSTAR consortium of diabetes specialists, regenerative
medicine researchers, biotech industrialists, and clinicians is to significantly
impact the management and treatment of the complications of DM.
REDDSTAR is novel in its reach across the control of blood glucose and the
improvement of a range of six serious diabetic tissue complications:
retinopathy, cardiomyopathy, nephropathy, wound healing, neuropathy, and
bone fracture repair.
met for the successful clinical translation of these studies from
animal model to the patient beside.
The route of administration of MSCs is an important variable.
Several modes of cell delivery (e.g., topical, intraocular, and sys-
temic) have been assessed in both pre-clinical and clinical studies
in recent times and these studies have illustrated the importance of
administration route in the successful outcome of these MSC stud-
ies. Systemic delivery is attractive as this may result in benefit for
multiple complications and has the potential to improve glycemic
control. Although and attractive option, the systemic delivery of
MSCs has some barriers such as homing of these cells to tissues
of interest with high efficiency and clinically meaningful engraft-
ment. A relatively high number of cells are required for injection
due to passive cell entrapment within non-specific tissues (179,
180) and this can potentially lead to unwanted effects and reduced
efficacy of transplanted cells. Topical application may be a very
relevant alternate strategy for some complications such as dia-
betic foot ulcers but this is approach can be limited by localized
vascular damage as a result of the diabetic milieu at the site of
administration.
It has been shown that the duration and degree of cell expansion
and culture has an impact on MSC morphology, differentiation,
viability, and migratory properties. MSCs not only undergo phe-
notypic changes in culture and during passage (size, morphology,
and cell surface marker expression) (181), but also lose capac-
ity for functional proliferation and differentiation potential (181,
182). In addition, their ability for cytokine production is altered
(182). Thus a delicate balance between culture expansion to gain
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sufficient numbers of MSCs for therapeutic application and long-
term culture effects needs to be met. The timing of cell delivery
and number of cells delivered are very important however there is
still a lack of information as to the optimal cell doses that provide
preclinical and clinical efficacy.
Despite numerous studies on the transplantation of MSCs in
patient and animal models, insight into the exact mechanisms of
action underlying their beneficial effect remains vague. Adequate
pre-clinical animal models are required to accurately represent the
pathological long-term effects of DM on the host system. There
are limitations in the current rodent models of diabetic complica-
tions, which tend to show early metabolic and functional disorders
but lack marked structural pathology, thus there is uncertainty as
to whether investigators are studying mechanisms pertinent to
overall pathological damage in humans (93).
An added complication in the scale up of MSC-based technolo-
gies is the need to tightly control the microenvironment of the
cell. Detailed investigations of how the microenvironment affects
the immunosuppressive effects of MSC are still lacking and are
required as cell-to-cell contact and soluble factors are thought
to be key aspects of MSC-mediated immunosuppression (56). A
major challenge is the large scale production of MSCs under GMP
conditions and issues of MSC heterogeneity. Furthermore, meth-
ods for transportation of MSC-based products without affecting
their viability and efficacy are important along with issues related
to cryopreservation.
The choice of an autologous or allogeneic approach is an impor-
tant consideration as the former may be limited by disease-induced
cell dysfunction and the latter by an immune response to the trans-
planted cells. As indicated previously, historical opinions that the
immunomodulatory functions of MSCs results in immune privi-
lege for allogeneic MSC transplants are being challenged (79–81)
with the recommendation that the anti-donor immune responses
elicited by allo-MSCs be studied in more detail.
An additional complication in the clinical translation of MSC
therapy is possible malignant transformation and cytogenetic
aberrations of MSCs. While most studies have reported no ill
effects of MSC transplantation, there are some conflicting reports
in the literature. There are some reports of increased tumor for-
mation in animals due to the immune suppressive effect of MSCs
especially with allogeneic transplants (183) and in vitro obser-
vations of sarcoma after culture of murine MSC (184). Other
studies have indicated a tumor-suppressive activity of MSC after
preactivation with TNF-α (185).
Preclinical animal models are important to test MSC efficacy
and mode of action but also are important tools to provide essen-
tial information for clinical testing such as safety, toxicity, phar-
macokinetics, and pharmacodynamics. The positive pre-clinical
data on safety and efficacy generated from a variety of MSC
investigations has prompted a huge surge in clinical investiga-
tions of MSC therapy. Since the first reported clinical trial of
MSCs (186), in excess of 100 clinical trials involving over 3000
human subjects have been performed and no severe adverse events
have been reported (187, 188). Thus, even with the reported con-
cerns over possible malignant transformation above, worldwide
clinical studies of both autologous and allogeneic MSC adminis-
tration have confirmed clinical safety and initial efficacy. A search
of the ClinicalTrials.Gov website1 reveals there are currently 243
open studies of MSC safety and efficacy in the treatment of
human diseases, such as acute Graft Versus Host Disease, Acute
Lymphoblastic Leukemia, Brain ischemia, and Parkinson’s dis-
ease. In relation to DM, there are currently 14 open clinical
trials using MSCs to treat T1DM, T2DM, or their associated
complications.
CONCLUSION
Mesenchymal stromal cells have been highlighted as a promis-
ing regenerative therapy due to their multipotency but also due
to their paracrine secretion of angiogenic factors, cytokines, and
immunomodulatory substances. A variety of pre-clinical and ini-
tial clinical studies have indicated that MSCs have potential as
a regenerative medicine in diabetes-associated microvascular and
secondary diabetic complications. MSC therapies do offer benefits
in comparison to other cell-based therapies such as ESC or iPSC in
that there are no ethical issues, no sourcing problems, less risk of
unrestricted growth, and thus far no adverse effects in clinical trials
have been reported. There is increased need for additional in vitro
and in vivo studies to fully describe in detail the mechanisms of
MSC-mediated cell therapy, and challenges remain in terms of
engraftment, persistence, tissue targeting, and cell manufacture.
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